;PMID: 8198573 ;source_file_2852.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..54] = [t:0..54] ;1)sentence:[e:60..244] = [t:60..244] ;2)section:[e:248..310] = [t:248..310] ;3)section:[e:314..377] = [t:314..377] ;4)sentence:[e:381..632] = [t:381..632] ;5)sentence:[e:633..840] = [t:633..840] ;6)sentence:[e:841..1094] = [t:841..1094] ;7)sentence:[e:1096..1302] = [t:1096..1302] ;8)section:[e:1306..1350] = [t:1306..1350] ;section 0 Span:0..54 ;Biochem Biophys Res Commun. 1994 May 30;201(1):180-5. (SEC (FRAG (NNP:[0..7] Biochem) (NNP:[8..15] Biophys) (NNP:[16..19] Res) (NNP:[20..26] Commun) (.:[26..27] .) (CD:[29..33] 1994) (NNP:[34..37] May) (CD:[38..40] 30) (CD:[40..44] ;201) (-LRB-:[44..45] -LRB-) (CD:[45..46] 1) (-RRB-:[46..47] -RRB-) (::[47..48] :) (CD:[48..51] 180) (CD:[51..53] -5) (.:[53..54] .))) ;sentence 1 Span:60..244 ;Anti-beta 2 subunit antisense oligonucleotides modulate the surface ;expression of the alpha 1 subunit of N-type omega-CTX sensitive Ca2+ ;channels in IMR 32 human neuroblastoma cells. ;[173..182]:gene-protein:"omega-CTX" ;[193..206]:gene-protein:"Ca2+ channels" ;[224..237]:malignancy-type:"neuroblastoma" (SENT (S-HLN (NP-SBJ (NML (AFX:[60..64] Anti) (HYPH:[64..65] -) (NML (SYM:[65..69] beta) (CD:[70..71] 2)) (NN:[72..79] subunit)) (JJ:[80..89] antisense) (NNS:[90..106] oligonucleotides)) (VP (VBP:[107..115] modulate) (NP (NP (DT:[116..119] the) (NN:[120..127] surface) (NN:[128..138] expression)) (PP (IN:[140..142] of) (NP (NP (DT:[143..146] the) (NML (SYM:[147..152] alpha) (CD:[153..154] 1)) (NN:[155..162] subunit)) (PP (IN:[163..165] of) (NP (NML (NN:[166..167] N) (HYPH:[167..168] -) (NN:[168..172] type)) (ADJP (NN:[173..182] omega-CTX) (JJ:[183..192] sensitive)) (NN:[193..197] Ca2+) (NNS:[198..206] channels)))))) (PP-LOC (IN:[207..209] in) (NP (NML (NN:[210..213] IMR) (CD:[214..216] 32)) (JJ:[218..223] human) (NN:[224..237] neuroblastoma) (NNS:[238..243] cells)))) (.:[243..244] .))) ;section 2 Span:248..310 ;Tarroni P, Passafaro M, Pollo A, Popoli M, Clementi F, Sher E. (SEC (FRAG (NNP:[248..255] Tarroni) (NNP:[256..258] P,) (NNP:[259..268] Passafaro) (NNP:[269..271] M,) (NNP:[272..277] Pollo) (NNP:[278..279] A) (,:[279..280] ,) (NNP:[281..287] Popoli) (NNP:[288..290] M,) (NNP:[291..299] Clementi) (NNP:[300..301] F) (,:[301..302] ,) (NNP:[303..307] Sher) (NNP:[308..310] E.))) ;section 3 Span:314..377 ;Department of Medical Pharmacology, University of Milan, Italy. (SEC (FRAG (NNP:[314..324] Department) (IN:[325..327] of) (NNP:[328..335] Medical) (NNP:[336..348] Pharmacology) (,:[348..349] ,) (NNP:[350..360] University) (IN:[361..363] of) (NNP:[364..369] Milan) (,:[369..370] ,) (NNP:[371..376] Italy) (.:[376..377] .))) ;sentence 4 Span:381..632 ;High voltage activated Ca2+ channels are heteropolymeric complexes in which ;the alpha 1 subunit forms the channel, while the alpha 2-delta and beta ;subunits are important for the assembly and regulation of the biophysical ;properties of the channel. ;[404..417]:gene-protein:"Ca2+ channels" (SENT (S (NP-SBJ (NML (JJ:[381..385] High) (NN:[386..393] voltage)) (VBN:[394..403] activated) (NN:[404..408] Ca2+) (NNS:[409..417] channels)) (VP (VBP:[418..421] are) (NP-PRD (NP (JJ:[422..437] heteropolymeric) (NNS:[438..447] complexes)) (SBAR (WHPP-3 (IN:[448..450] in) (WHNP (WDT:[451..456] which))) (S (NP-SBJ (DT:[457..460] the) (NML (SYM:[462..467] alpha) (CD:[468..469] 1)) (NN:[470..477] subunit)) (VP (VBZ:[478..483] forms) (NP (DT:[484..487] the) (NN:[488..495] channel)) (PP-3 (-NONE-:[495..495] *T*)))))) (,:[495..496] ,) (SBAR-ADV (IN:[497..502] while) (S (NP-SBJ (DT:[503..506] the) (NML (NML (NML (NML-1 (SYM:[507..512] alpha) (CD:[513..514] 2)) (HYPH:[514..515] -) (SYM:[515..520] delta)) (NML-2 (-NONE-:[520..520] *P*))) (CC:[521..524] and) (NML (NML (NML-1 (-NONE-:[524..524] *P*)) (SYM:[525..529] beta)) (NML-2 (NNS:[530..538] subunits))))) (VP (VBP:[539..542] are) (ADJP-PRD (JJ:[544..553] important) (PP (IN:[554..557] for) (NP (NP (DT:[558..561] the) (NN:[562..570] assembly) (CC:[571..574] and) (NN:[575..585] regulation)) (PP (IN:[586..588] of) (NP (NP (DT:[589..592] the) (JJ:[593..604] biophysical) (NNS:[605..615] properties)) (PP (IN:[616..618] of) (NP (DT:[619..622] the) (NN:[624..631] channel)))))))))))) (.:[631..632] .))) ;sentence 5 Span:633..840 ;We have tested the role of the beta 2 subunit on the expression and ;electrophysiological properties of the omega-conotoxin GVIA-sensitive Ca2+ ;channel expressed in the IMR 32 human neuroblastoma cell line. ;[741..756]:gene-protein:"omega-conotoxin" ;[772..785]:gene-protein:"Ca2+ channel" ;[816..829]:malignancy-type:"neuroblastoma" (SENT (S (NP-SBJ (PRP:[633..635] We)) (VP (VBP:[636..640] have) (VP (VBN:[641..647] tested) (NP (NP (DT:[648..651] the) (NN:[652..656] role)) (PP (IN:[657..659] of) (NP (DT:[660..663] the) (NML (SYM:[664..668] beta) (CD:[669..670] 2)) (NN:[671..678] subunit))) (PP (IN:[679..681] on) (NP (NP (NP (DT:[682..685] the) (NN:[686..696] expression)) (CC:[697..700] and) (NP (JJ:[702..722] electrophysiological) (NNS:[723..733] properties))) (PP (IN:[734..736] of) (NP (NP (DT:[737..740] the) (NN:[741..756] omega-conotoxin) (ADJP (NN:[757..761] GVIA) (HYPH:[761..762] -) (JJ:[762..771] sensitive)) (NN:[772..776] Ca2+) (NN:[778..785] channel)) (VP (VBN:[786..795] expressed) (NP (-NONE-:[795..795] *)) (PP (IN:[796..798] in) (NP (DT:[799..802] the) (NML (NN:[803..806] IMR) (CD:[807..809] 32)) (JJ:[810..815] human) (NN:[816..829] neuroblastoma) (NN:[830..834] cell) (NN:[835..839] line))))))))))) (.:[839..840] .))) ;sentence 6 Span:841..1094 ;Anti-beta 2 subunit antisense oligonucleotides supplied to the cells in ;culture induced a time-dependent increase in the number of ;[125I]-omega-conotoxin binding sites on the cell surface, which was not ;paralleled by an increase in current amplitude. ;[980..996]:gene-protein:"-omega-conotoxin" (SENT (S (NP-SBJ (NP (NML (AFX:[841..845] Anti) (HYPH:[845..846] -) (NML (SYM:[846..850] beta) (CD:[851..852] 2)) (NN:[854..861] subunit)) (JJ:[862..871] antisense) (NNS:[872..888] oligonucleotides)) (VP (VBN:[889..897] supplied) (NP (-NONE-:[897..897] *)) (PP (TO:[898..900] to) (NP (DT:[901..904] the) (NNS:[905..910] cells))) (PP (IN:[911..913] in) (NP (NN:[914..921] culture))))) (VP (VBD:[922..929] induced) (NP (NP (NP (DT:[930..931] a) (ADJP (NN:[933..937] time) (HYPH:[937..938] -) (JJ:[938..947] dependent)) (NN:[948..956] increase)) (PP (IN:[957..959] in) (NP (NP (DT:[960..963] the) (NN:[964..970] number)) (PP (IN:[971..973] of) (NP (NN:[974..980] -LSB-125I-RSB-) (NN:[980..996] -omega-conotoxin) (NN:[997..1004] binding) (NNS:[1005..1010] sites))))) (PP (IN:[1011..1013] on) (NP (DT:[1015..1018] the) (NN:[1019..1023] cell) (NN:[1024..1031] surface)))) (,:[1031..1032] ,) (SBAR (WHNP-1 (WDT:[1033..1038] which)) (S (NP-SBJ-1 (-NONE-:[1038..1038] *T*)) (VP (VBD:[1039..1042] was) (RB:[1043..1046] not) (VP (VBN:[1047..1057] paralleled) (NP-1 (-NONE-:[1057..1057] *)) (PP (IN:[1058..1060] by) (NP-LGS (NP (DT:[1061..1063] an) (NN:[1064..1072] increase)) (PP (IN:[1073..1075] in) (NP (NN:[1076..1083] current) (NN:[1084..1093] amplitude))))))))))) (.:[1093..1094] .))) ;sentence 7 Span:1096..1302 ;We suggest that a reduction in the expression of beta 2 stimulates the ;transport to the plasma membrane of non-functioning Ca2+ channels and, in ;particular, of the alpha 1 omega-conotoxin binding subunit. ;[1220..1233]:gene-protein:"Ca2+ channels" ;[1270..1285]:gene-protein:"omega-conotoxin" (SENT (S (NP-SBJ (PRP:[1096..1098] We)) (VP (VBP:[1099..1106] suggest) (SBAR (IN:[1107..1111] that) (S (NP-SBJ (NP (DT:[1112..1113] a) (NN:[1114..1123] reduction)) (PP (IN:[1124..1126] in) (NP (NP (DT:[1127..1130] the) (NN:[1131..1141] expression)) (PP (IN:[1142..1144] of) (NP (SYM:[1145..1149] beta) (CD:[1150..1151] 2)))))) (VP (VBZ:[1152..1162] stimulates) (NP (NP (DT:[1163..1166] the) (NN:[1167..1176] transport)) (PP (TO:[1178..1180] to) (NP (DT:[1181..1184] the) (NN:[1185..1191] plasma) (NN:[1192..1200] membrane))) (PP (PP (IN:[1201..1203] of) (NP (ADJP (AFX:[1204..1207] non) (HYPH:[1207..1208] -) (VBG:[1208..1219] functioning)) (NN:[1220..1224] Ca2+) (NNS:[1225..1233] channels))) (CC:[1234..1237] and) (,:[1237..1238] ,) (PP (PP (IN:[1239..1241] in) (NP (JJ:[1242..1252] particular))) (,:[1252..1253] ,) (IN:[1254..1256] of) (NP (DT:[1258..1261] the) (NML (SYM:[1262..1267] alpha) (CD:[1268..1269] 1)) (NML (NN:[1270..1285] omega-conotoxin) (NN:[1286..1293] binding)) (NN:[1294..1301] subunit))))))))) (.:[1301..1302] .))) ;section 8 Span:1306..1350 ;PMID: 8198573 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1306..1310] PMID) (::[1310..1311] :) (CD:[1312..1319] 8198573) (NN:[1320..1321] -LSB-) (NNP:[1321..1327] PubMed) (::[1328..1329] -) (NN:[1330..1337] indexed) (IN:[1338..1341] for) (NNP:[1342..1350] MEDLINE-RSB-)))